<p>Van Hulzen Asset Management LLC 在最近向证券交易委员会的披露中表示，在第一季度减少了对强生（NYSE:JNJ - 免费报告）22.5% 的持股。该公司在此期间出售了 34,558 股后，持有 118,842 股强生的股票。强生约占 Van Hulzen Asset Management LLC 投资组合的 1.8%，使其成为该公司第 12 大持仓。截止最近一个季度末，Van Hulzen Asset Management LLC 在强生的持股价值为 19,709,000 美元。</p>
<ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
<p>其他大型投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在强生的股份增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股强生的股票，价值 7,502,000 美元，此前在此期间又购买了 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的股份增加了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股强生的股票，价值 5,648,000 美元，此前在上个季度又收购了 1,022 股。Burling Wealth Partners LLC 在第四季度收购了强生的新股份，价值为 3,908,000 美元。Integrated Wealth Concepts LLC 在第四季度将其在强生的股份增加了 6.1%。Integrated Wealth Concepts LLC 现在持有 108,473 股强生的股票，价值 15,687,000 美元，此前在上个季度又购买了 6,247 股。最后，Empire Financial Management Company LLC 在第四季度将其在强生的持仓增加了 18.0%。Empire Financial Management Company LLC 现在持有 17,882 股强生的股票，价值 2,586,000 美元，此前在上个季度又购买了 2,732 股。69.55% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>强生股票表现</h2>
<p>强生的股票在周五开盘价为 178.8990 美元。强生的 12 个月低点为 140.68 美元，12 个月高点为 180.61 美元。该公司的 50 日移动平均线为 163.04 美元，200 日移动平均线为 159.05 美元。该公司的速动比率为 0.76，流动比率为 1.01，债务与股本比率为 0.50。该公司的市值为 4308.5 亿美元，市盈率为 19.13，市盈增长比率为 2.28，贝塔值为 0.41。</p>
<ul>
<li>3 大强劲收益的高分红股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 7 月 16 日，报告每股收益（EPS）为 2.77 美元，超出分析师一致预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，该公司每股收益为 2.82 美元。强生的收入同比增长 5.8%。强生已将 2025 财年的指引设定为每股收益 10.800-10.900 美元。股票分析师预计强生在当前财年将发布每股收益 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近还宣布了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登记投资者将获得 1.30 美元的分红。除息日为 8 月 26 日（星期二）。这代表着年化分红为 5.20 美元，收益率为 2.9%。强生的分红支付比率（DPR）目前为 55.61%。</p>
<h2>分析师评级上调和下调</h2>
<ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
<p>几位股票研究分析师最近对该公司发表了评论。Barclays 将强生的目标价从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该公司 “持平” 评级。Guggenheim 在 7 月 17 日的研究报告中重申了 “中性” 评级，并将强生的目标价设定为 167.00 美元（此前为 164.00 美元）。加拿大皇家银行将强生的目标价从 181.00 美元上调至 185.00 美元，并在 7 月 17 日的研究报告中给予该股票 “跑赢大盘” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的研究报告中将该股票的目标价从 169.00 美元下调至 153.00 美元。最后，Benchmark 在 4 月 24 日的研究报告中将强生的评级上调至 “强力买入”。两位分析师对该股票给予强力买入评级，九位给予买入评级，九位对该公司的股票给予持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 176.29 美元。</p>
<p><strong>获取我们最新的 JNJ 股票分析</strong></p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>如何开始投资于便士股票</li>
<li>小型股，大潜力：你应该了解的 3 家科技颠覆者</li>
<li>电话会议和个人投资者</li>
<li>在财报失利后，沃尔玛仍然是顶级消费品选择</li>
<li>高分红房地产投资信托：它们是理想的多元化方式吗？</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Van Hulzen Asset Management LLC 在第一季度减少了对强生（NYSE: JNJ）22.5% 的持股，目前持有 118,842 股，价值约为 1970 万美元。其他投资者，包括 Brighton Jones LLC 和 Hudson Value Partners LLC 也调整了他们的持仓。JNJ 股票开盘价为 178.90 美元，12 个月的价格区间为 140.68 美元至 180.61 美元。该公司报告第二季度每股收益为 2.77 美元，超出预期，并宣布季度股息为 1.30 美元，收益率为 2.9%</p>

<p>Van Hulzen Asset Management LLC lessened its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 22.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 118,842 shares of the company's stock after selling 34,558 shares during the period. Johnson &amp; Johnson comprises approximately 1.8% of Van Hulzen Asset Management LLC's portfolio, making the stock its 12th biggest position. Van Hulzen Asset Management LLC's holdings in Johnson &amp; Johnson were worth $19,709,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Van Hulzen Asset Management LLC 在最近向证券交易委员会的披露中表示，在第一季度减少了对强生（NYSE:JNJ - 免费报告）22.5% 的持股。该公司在此期间出售了 34,558 股后，持有 118,842 股强生的股票。强生约占 Van Hulzen Asset Management LLC 投资组合的 1.8%，使其成为该公司第 12 大持仓。截止最近一个季度末，Van Hulzen Asset Management LLC 在强生的持股价值为 19,709,000 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Johnson &amp; Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC increased its stake in shares of Johnson &amp; Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Burling Wealth Partners LLC acquired a new stake in Johnson &amp; Johnson during the fourth quarter valued at $3,908,000. Integrated Wealth Concepts LLC grew its stake in Johnson &amp; Johnson by 6.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 108,473 shares of the company's stock valued at $15,687,000 after purchasing an additional 6,247 shares in the last quarter. Finally, Empire Financial Management Company LLC increased its position in Johnson &amp; Johnson by 18.0% in the 4th quarter. Empire Financial Management Company LLC now owns 17,882 shares of the company's stock worth $2,586,000 after purchasing an additional 2,732 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在强生的股份增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股强生的股票，价值 7,502,000 美元，此前在此期间又购买了 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的股份增加了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股强生的股票，价值 5,648,000 美元，此前在上个季度又收购了 1,022 股。Burling Wealth Partners LLC 在第四季度收购了强生的新股份，价值为 3,908,000 美元。Integrated Wealth Concepts LLC 在第四季度将其在强生的股份增加了 6.1%。Integrated Wealth Concepts LLC 现在持有 108,473 股强生的股票，价值 15,687,000 美元，此前在上个季度又购买了 6,247 股。最后，Empire Financial Management Company LLC 在第四季度将其在强生的持仓增加了 18.0%。Empire Financial Management Company LLC 现在持有 17,882 股强生的股票，价值 2,586,000 美元，此前在上个季度又购买了 2,732 股。69.55% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>Shares of JNJ opened at $178.8990 on Friday. Johnson &amp; Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company's fifty day moving average is $163.04 and its 200-day moving average is $159.05. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $430.85 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.</p>
<div class="lb-trans"><p>强生的股票在周五开盘价为 178.8990 美元。强生的 12 个月低点为 140.68 美元，12 个月高点为 180.61 美元。该公司的 50 日移动平均线为 163.04 美元，200 日移动平均线为 159.05 美元。该公司的速动比率为 0.76，流动比率为 1.01，债务与股本比率为 0.50。该公司的市值为 4308.5 亿美元，市盈率为 19.13，市盈增长比率为 2.28，贝塔值为 0.41。</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 大强劲收益的高分红股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 7 月 16 日，报告每股收益（EPS）为 2.77 美元，超出分析师一致预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，该公司每股收益为 2.82 美元。强生的收入同比增长 5.8%。强生已将 2025 财年的指引设定为每股收益 10.800-10.900 美元。股票分析师预计强生在当前财年将发布每股收益 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登记投资者将获得 1.30 美元的分红。除息日为 8 月 26 日（星期二）。这代表着年化分红为 5.20 美元，收益率为 2.9%。强生的分红支付比率（DPR）目前为 55.61%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
</div><p>Several equities research analysts recently commented on the company. Barclays boosted their price target on Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Guggenheim restated a &#34;neutral&#34; rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson &amp; Johnson from $181.00 to $185.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Benchmark upgraded shares of Johnson &amp; Johnson to a &#34;strong-buy&#34; rating in a research note on Thursday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $176.29.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了评论。Barclays 将强生的目标价从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该公司 “持平” 评级。Guggenheim 在 7 月 17 日的研究报告中重申了 “中性” 评级，并将强生的目标价设定为 167.00 美元（此前为 164.00 美元）。加拿大皇家银行将强生的目标价从 181.00 美元上调至 185.00 美元，并在 7 月 17 日的研究报告中给予该股票 “跑赢大盘” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的研究报告中将该股票的目标价从 169.00 美元下调至 153.00 美元。最后，Benchmark 在 4 月 24 日的研究报告中将强生的评级上调至 “强力买入”。两位分析师对该股票给予强力买入评级，九位给予买入评级，九位对该公司的股票给予持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 176.29 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 JNJ 股票分析</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to start investing in penny stocks</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>Conference Calls and Individual Investors</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>如何开始投资于便士股票</li>
<li>小型股，大潜力：你应该了解的 3 家科技颠覆者</li>
<li>电话会议和个人投资者</li>
<li>在财报失利后，沃尔玛仍然是顶级消费品选择</li>
<li>高分红房地产投资信托：它们是理想的多元化方式吗？</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Van Hulzen Asset Management LLC 减持了强生 $JNJ 的股份